Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

VRBPAC panel votes in favor of Pfizer-BioNTech vaccine for 5- to 11-year-olds

By Brian Buntz | October 26, 2021

FDA logoFDA’s Vaccines and Related Biological Products Advisory Committee has endorsed the Pfizer-BioNTech (NYSE:PFE/NSDQ:BNTX) COVID-19 vaccine for children 5 to 11.

A total of 17 out of 18 members voted that the vaccine’s benefits outweighed the risk in the age group.

VRBPAC member Dr. Michael Kurilla, the director of NIH’s Division of Clinical Innovation, abstained from voting. He had advocated that children with a prior COVID-19 infection receive alternate dosing.

The committee based its conclusions on data from Pfizer, which found that two 10-µg doses of the vaccine were generally well tolerated and 90.7% effective against COVID-19. Pfizer also provided some immunobridging data.

Before the vaccine is available for children in this lower age group, FDA and CDC need to issue formal recommendations concerning its use in children 5 to 11. There are roughly 28 million children in that age group in the U.S.

Several panelists said they were less worried about the risk of vaccine-associated myocarditis in younger children compared with adolescents and young adults.

Panelists also expressed some reservations about recommending the vaccine based on the limited availability of data.

VRBPAC member Dr. Cody Meissner contrasted the Pfizer-BioNTech vaccine with the measles, mumps and rubella (MMR) vaccine that has been widely used in children.

“We have a very good sense of what the adverse events are” for the MMR vaccine, Meissner said. “We do not have that with this particular messenger RNA vaccine.”

While some children who receive the Pfizer-BioNTech vaccine “may very well derive benefit,” he added, “there are other children who may be at increased risk of myocarditis.”

“I was a little disappointed that the clinical trials for children didn’t start until June 1 of this year, whereas this time last year, we were evaluating the clinical trials for 18-year-olds and above for the Pfizer vaccine and then quickly thereafter for the Moderna vaccine,” said Dr. Patrick Moore, a temporary VRBPAC voting member.

COVID-19 hospitalizations involving children in the relevant age group are rare. That said, COVID-19 has been estimated as the eighth most common cause of death in children during the pandemic, according to VRBPAC member Dr. Amanda Cohn.

PFE shares ticked just under 1% apiece to $43.56 today. BNTX shares dipped 0.86% apiece to $292.39, but the stock recovered in after-hours trading, rising 1.58% to $297.00.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Pfizer, SARS-CoV-2
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50